SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

Canaccord rates Opthea a buy with a $1.25 price target. But the broker thinks it could shoot as high as ... Read More The ...

The Gonzales Lab at UNR Med, led by Albert Gonzales, Ph.D., assistant professor of physiology and cell biology, spearheaded ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Initial interim 52-week results from Phase 2b Population Extension cohort of PRISM clinical trial to be presented by Dante Pieramici, M.D., a ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Pegcetacoplan (Syfovre) is now approved in Australia for treating geographic atrophy (GA) secondary to age-related macular ...

HDL cholesterol levels demonstrate a U-shaped association with AMD, in which both high and low levels elevate risk.

Pharmaceuticals announced that the Therapeutic Goods Administration, TGA, has approved SYFOVRE or pegcetacoplan, for the ...

ONS-5010 (bevacizumab-vikg) was found to be noninferior to ranibizumab for neovascular age-related macular degeneration at week 12.

Phone apps for people with low vision can also be a big help, Mortazavi says. These include magnification apps like ...